Nephrology

Lege Artis Medicinae

FEBRUARY 20, 2024

[Reno- and cardioprotective effects of sodium-glucose cotransporter 2 inhibitors beyond treating diabetes mellitus ]

AMBRUS Csaba, BENCZÚR Béla

[SGLT2-inhibitors, originally used as anti­dia­­betics, improved unexpectedly the outcome of cardiac diseases (mainly heart failure) and nearly halved the risk of renal events of diabetic patients. More recently, administering these drugs decreased significantly the morbidity and mortality in primary renal endpoint studies and among patients with heart failure – in diabetic and non-diabetic patients respectively. Con­cer­ning these recent outcomes and according to international and domestic guidelines, SGLT-2 inhibitors are considered as first line medications in both chronic kidney dis­ease and the whole spectrum of chronic heart failure, and they should be initiated as early as possible in these conditions. Since the beginning of 2024, these drugs which changed significantly the outcome of these diseases can be prescribed with greater support of Hungarian public financing not only for type 2 diabetic patients but non-diabetics too with chronic kidney diseases and heart failure with reduced ejection fraction. ]

HUN 2024;34(1-2)

Hypertension and nephrology

DECEMBER 18, 2023

[Chronic kidney disease and obesity]

FREISINGER Lilla, NÉMETHY Orsolya, LELOVICS Zsuzsanna, SZLOVÁK Edina, DOLGOS Szilveszter

[Nowadays, the epidemic spread of obesity is mainly linked to changing environmental factors and is a serious public health problem. Obesity alone can be associated with increased mortality, but obesity is also an independent risk factor for several chronic diseases such as diabetes, hypertension and chronic kidney disease which have a major public health burden.]

HUN 2023;27(06)

Hypertension and nephrology

DECEMBER 18, 2023

[Cardio-renal-metabolic approach in medicine – thoughts, considerable information based on the new recommendations regarding SGLT2 inhibitors and GLP1 receptor agonists]

WAGNER László

[Common complications of type 2 diabetes are chronic kidney failure and chronic heart failure. However, chronic renal failure and chronic heart failure can contribute to the development and deterioration of each other, and can be present earlier and more severely in the case of diabetes. Furthermore, type 2 diabetes might also occur more frequently in case of chronic kidney- and heart failure. All of these are often accompanied by atherosclerotic cardiovascular disease and hypertension.]

HUN 2023;27(06)

Hypertension and nephrology

DECEMBER 18, 2023

[Complex therapeutic protection with SGLT2 inhibitors, focusing on the kidney]

LÉGRÁDY Péter

[In the EMPA-REG Outcome trial, it was already observed that cardiovascular (10.5% vs. 12.1%) and renal (1.7% vs. 3.1%) outcomes were better with empagliflozin treatment compared to placebo. The favorable effects of empagliflozin were consistent across the KDIGO risk categories. CVOT trials conducted with other SGLT2 inhibitors also concluded with promising renoprotective results.]

HUN 2023;27(06)

Hypertension and nephrology

DECEMBER 18, 2023

[Role of renal P2Y12 receptors in lithium-induced polyuria]

RADÓ János

[Clinicians and investigators know since ages that increased production of prostaglandins play a significant role in the pathogenesis of polyuria of patients with Bartter syndrome.]

HUN 2023;27(06)

Hypertension and nephrology

DECEMBER 18, 2023

[The Hungarian Kidney Foundation "Lifetime Achievement Award for Nephrology" László Szalay]

[He was awarded the 2023 Lifetime Achievement Award for Nephrology by the Hungarian Kidney Foundation, which was presented by Professor László Rosivall at the XXXVIII General Meeting of the Hungarian Nephrology Society in Eger, Hungary.]

HUN 2023;27(06)